USPTO serial 79222834
CAELUS PHARMACEUTICALS
Reviewed by CopyMark Law Group
Reg. 5619593Status 707Registered
- Filing date
- Status date
- Registration date
- Dec 4, 2018
- Examiner
- CALIENDO, COURTNEY MICHELLE
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with CAELUS PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Roberto Ledesma
Roberto Ledesma Law Office of Roberto LedesmaP.O. Box 230692New York, NY 10023United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for treating cardiometabolic disorders; dietetic foodstuffs adapted for medical use and dietetic substances, namely, dietetic foods adapted for medical use; food supplements for human beings; medical preparations and articles for the treatment of cardiometabolic disorders; [ diagnostic preparations for medical use; pharmaceutical products and natural medicines, both for the treatment of cardiometabolic disorders; vaccines; ] pharmaceutical preparations, namely, medicines [ and vaccines, ] for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; pharmaceutical preparations, namely, medicines for the treatment of diabetes mellitus, [ Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic preparations, namely, dietary supplements; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the prevention of diabetes mellitus [ , Crohn's disease and ulcerative colitis disease ] ; dietary food preparations, namely, dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the treatment of diabetes mellitus [ , Crohn's disease, ulcerative colitis disease ] and metabolic syndrome being insulin resistance; medical preparations, namely, cultures of microorganisms for medical use, and bacterial preparations for medical use [ ; chemicals for the diagnosis of diabetes mellitus, Crohn's disease and ulcerative colitis disease; vaccine preparations for human use ] | ACTIVE | — |
| 010 | [ Medical apparatus and instruments, namely, for use in treating cardiovascular disease or diabetes, for monitoring vital signs, blood sugar levels, AGE-levels in the skin and gut/skin microbiota composition; Medical diagnostic, testing and monitoring equipment, namely, medical diagnostic equipment for detecting and monitoring blood sugar levels, AGEs and microbiome composition; testing apparatus for medical use, namely, medical devices for testing blood glucose, microbiome composition in gut and on the skin, testing AGE-levels, and for testing the levels of butyrate in breath analysis; measuring devices for medical use, namely, medical device for measuring glucose, insulin, butyrate, propionate, gut and skin microbiome; testing apparatus for medical use, namely, blood testing apparatus, apparatus for analyzing feces or respiratory gas, medical measuring devices for medical use, namely, devices for measuring microorganisms or gas; medical test kits for home monitoring of diabetes ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Caelus Pharmaceuticals B.V.
- Other trademarks owned by Caelus Pharmaceuticals B.V.
- Other trademarks owned by Caelus Pharmaceuticals B.V.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named CAELUS PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 10, 2026 | Further Decision Processed by IB | — | |
| Jul 8, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jul 8, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jul 8, 2026 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Dec 7, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 7, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 7, 2025 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Apr 7, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 14, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Dec 30, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 4, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 5, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 18, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 18, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 4, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 4, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 18, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 18, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 15, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 29, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 29, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 29, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 13, 2018 | ALIE | ASSIGNED TO LIE | — |
| Aug 2, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 2, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 2, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 2, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 6, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 16, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 15, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 12, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 12, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 23, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 23, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 22, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 19, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 18, 2017 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Dec 14, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |